NOV 25, 2021 3:00 AM PST

Could an Anti-Cancer Drug Treat Diabetes?

WRITTEN BY: Katie Kokolus

Diabetes and cancer are two common diseases that share many similar risk factors. People with diabetes are also at higher risk of developing many types of cancer. While both diseases impact an increasing number of people each year, the possibility of a drug that can mitigate both cancer and diabetes in patients would be very enticing.  

A report recently published in the Mayo Clinic Proceedings demonstrates a possible new application for an established chemotherapy called dasatinib. Approved by the FDA in 2006 to treat acute myeloid leukemia, dasatinib is a small molecule inhibitor that can easily enter cells and act on proteins inside the cell. Dasatinib’s anti-cancer effects are mediated when the drug binds to and inhibits tyrosine kinases, proteins that promote tumor growth.  

The researchers performed a retrospective stud, a type of study that looks back at data that has already been collected to investigate a new scientific question. In this study, the research team identified patients with type 2 diabetes mellitus who were treated with either dasatinib or imatinib, another tyrosine kinase inhibitor. They examined the patients’ medical records to collect data on health outcomes, including weight, serum glucose concentration, and A1c levels.  

The study found that serum glucose concentration was about 40 mg/dL lower in patients treated dasatinib compared to those treated with imatinib.  The dasatinib-treated patients also lost, on average, 5 kg, or about 5% of total body weight.  Additionally, A1c levels were reduced in dasatinib-treated patients. 

The investigators noted some limitations to their study.  A major limitation is highlighted by the fact that all the patients in the study were being treated for underlying cancer.  The authors did not have information on how aggressive each patient’s cancer presented.  However, because all patients included in the study had received at least one year of tyrosine kinase therapy, any patient who was not responding to the therapy would have likely tried an alternative therapy and thus would not be included in the study.  Additionally, the study's retrospective nature did not allow the investigators to consider other interventions impacting diabetic indicators, such as exercise and diet.  

Further study is needed to confirm the effectiveness of dasatinib as a diabetes medication and understand the potential mechanisms underlying the observed effects.  This study provides the rationale for further investigating this chemotherapy drug's potential repurposing to benefit diabetic patients. 

Sources: risk factorshigher riskMayo Clinic Proceedingsdasatinib, small molecule inhibitorimatinib

About the Author
  • PhD in Tumor Immunology. I am interested in developing novel strategies to improve the efficacy of immunotherapies used to extend cancer survivorship.
You May Also Like
AUG 25, 2021
Cell & Molecular Biology
Sino Biological's Listing on the Shenzhen Stock Exchange
AUG 25, 2021
Sino Biological's Listing on the Shenzhen Stock Exchange
China, August 16, 2021 - Sino Biological, Inc. (“Sino Biological” or the “Company”), a biot ...
SEP 27, 2021
Cancer
Inflammation Promotes Pancreatic Cancer Progression
SEP 27, 2021
Inflammation Promotes Pancreatic Cancer Progression
Inflammation occurs when the immune response, including immune cells and mediators they produce, protect you from danger ...
OCT 01, 2021
Health & Medicine
Eppendorf Award 2022: Call for Entries
OCT 01, 2021
Eppendorf Award 2022: Call for Entries
Eppendorf Award 2022: Call for Entries The Eppendorf Award for Young European Investigators, endowed with 20,000 EUR, is ...
JAN 07, 2022
Cancer
Crossing the Blood-Brain Barrier: Improving Experimental Models to Study Drug Delivery
JAN 07, 2022
Crossing the Blood-Brain Barrier: Improving Experimental Models to Study Drug Delivery
The blood-brain barrier (BBB) describes the complex vasculature network that delivers oxygen and nutrients to the brain. ...
JAN 10, 2022
Cancer
Race May Impact Radiation Efficacy in Prostate Cancer Patients
JAN 10, 2022
Race May Impact Radiation Efficacy in Prostate Cancer Patients
Racial disparities exist between Black and White populations in many types of cancer.  Researchers actively investi ...
JAN 13, 2022
Cancer
An Arthritis Drug Combats Chemoresistance in Pancreatic Cancer
JAN 13, 2022
An Arthritis Drug Combats Chemoresistance in Pancreatic Cancer
The American Cancer Society estimates the lifetime risk of pancreatic cancer at about 1 in 64. Pancreatic duct ...
Loading Comments...